Evaluation of labelingparameters of PSMA-617 with 213Bi for targeted alpha-radionuclide therapy of metastatic castration-resistant prostate cancer

被引：0
|
作者：
Khoshhosn, H. [1 ]
Davarpanah, M. [1 ]
Khoshhosn, H. [1 ]
Gravand, A. [1 ]
Tavakoli, Y. [1 ]
Soltani, N. [1 ]
Harati, M. [1 ]
Kalantari, B. [1 ]
Johri, F. [1 ]
机构：
[1] Pars Isotope Co, Tehran, Iran
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2023年 / 50卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
OP-720
引用
收藏
页码：S326 / S326
页数：1
相关论文
共 50 条
  • [31] 177Lu-labeled PSMA-617 radioligand therapy for metastatic castration-resistant prostate cancer: which pretreatment parameters would predict response?
    Sandler, I.
    Leibowitz-Amit, R.
    Smechov, M.
    Goshen, E.
    Malki, A.
    Eshet, Y.
    Berger, R.
    Ben-Haim, S.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 : S127 - S127
  • [32] Targeted α-Therapy of Metastatic Castration-Resistant Prostate Cancer with 225Ac-PSMA-617: Dosimetry Estimate and Empiric Dose Finding
    Kratochwil, Clemens
    Bruchertseifer, Frank
    Rathke, Hendrik
    Bronzel, Marcus
    Apostolidis, Christos
    Weichert, Wilko
    Haberkorn, Uwe
    Giesel, Frederik L.
    Morgenstern, Alfred
    JOURNAL OF NUCLEAR MEDICINE, 2017, 58 (10) : 1624 - 1631
  • [33] Renal and Salivary Gland Functions after Three Cycles of PSMA-617 Therapy Every Four Weeks in Patients with Metastatic Castration-Resistant Prostate Cancer
    Wollenweber, Tim
    Zisser, Lucia
    Kretschmer-Chott, Elisabeth
    Weber, Michael
    Grubmuller, Bernhard
    Kramer, Gero
    Shariat, Shahrokh F.
    Mitterhauser, Markus
    Schmitl, Stefan
    Vraka, Chrysoula
    Haug, Alexander R.
    Hacker, Marcus
    Hartenbach, Markus
    Rasul, Sazan
    CURRENT ONCOLOGY, 2021, 28 (05) : 3692 - 3704
  • [34] PSMA Radioligand Therapy (PRLT) of Metastatic Castration-Resistant Prostate Cancer: Safety, Efficacy and Dosimetry using the PSMA Inhibitor 617
    Kulkarni, H. R.
    Schuchardt, C.
    Singh, A.
    Niepsch, K.
    Baum, R. P.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2016, 43 : S139 - S139
  • [35] Intermittent Lu-177-PSMA-617 therapy of metastatic castration-resistant prostate cancer in early responders
    Mader, Nicolai
    Ngoc, Christina Nguyen
    Baumgarten, Justus
    Groener, Daniel
    Davis, Karen
    Wichert, Jennifer
    Tselis, Nikolaos
    Mandel, Philipp
    Gruenwald, Frank
    Sabet, Amir
    JOURNAL OF NUCLEAR MEDICINE, 2020, 61
  • [36] Promising 177Lu-PSMA-617 Therapy Results in Patients with Metastatic Castration-Resistant Prostate Cancer
    Brnjic, Antonio
    Frye, Sarah
    Botkin, Crystal
    Osman, Medhat
    JOURNAL OF NUCLEAR MEDICINE, 2021, 62
  • [37] Efficacy and Safety of 225Ac-PSMA-617-Targeted Alpha Therapy in Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis
    Ma, Jiao
    Li, Lanying
    Liao, Taiping
    Gong, Weidong
    Zhang, Chunyin
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [38] Re: 225Ac-PSMA-617 for PSMA-Targeting Alpha-radiation Therapy of Patients with Metastatic Castration-resistant Prostate Cancer
    Hadaschik, Boris
    EUROPEAN UROLOGY, 2016, 70 (06) : 1080 - 1081
  • [39] Outcomes for Patients with Metastatic Castration-Resistant Prostate Cancer and Liver Metastasis Receiving [177Lu]Lu- PSMA-617
    Muniz, Miguel
    Sartor, Oliver
    Orme, Jacob J.
    Koch, Regina M.
    Rosenow, Hana R.
    Mahmoud, Ahmed M.
    Andrews, Jack R.
    Kase, Adam M.
    Riaz, Irbaz B.
    Bilgin, Gokce Belge
    Thorpe, Matthew P.
    Kendi, A. Tuba
    Johnson, Geoffrey B.
    Ravi, Praful
    Kwon, Eugene D.
    Childs, Daniel S.
    JOURNAL OF NUCLEAR MEDICINE, 2024, 65 (12) : 1932 - 1938
  • [40] The efficacy and safety of 225Ac-PSMA-617 in metastatic castration-resistant prostate cancer
    Ma, Jiao
    Zhang, Yu
    Yangqing, Jiangchu
    Liu, Guangfu
    Wang, Junzheng
    Zhang, Chunyin
    FRONTIERS IN ONCOLOGY, 2025, 15
12345